Brill Livnat, Raposo Catarina, Rechtman Ariel, Zveik Omri, Levin Netta, Oiknine-Djian Esther, Wolf Dana G, Vaknin-Dembinsky Adi
Department of Neurology, Laboratory of Neuroimmunology, and Agnes-Ginges Center for Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
F. Hoffmann-La Roche, Basel, Switzerland.
Ann Neurol. 2022 Jun;91(6):796-800. doi: 10.1002/ana.26343. Epub 2022 Mar 24.
The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796-800.
随着第三剂疫苗接种的引入以及新出现的值得关注的变异株，对于接受B细胞清除治疗且对疫苗产生减弱的体液反应的多发性硬化症患者（pwMS）的血清学和T细胞反应提出了问题。本研究的目的是纵向评估在接受奥瑞珠单抗治疗的pwMS患者中，在第三剂疫苗接种前后对SARS-CoV-2 mRNA疫苗的体液和细胞反应。在接种第三剂疫苗后，初始接种后反应低或无反应的患者抗体滴度并未增加。在健康对照者和接受奥瑞珠单抗治疗的pwMS患者中，细胞反应在初始接种后6个月下降，在第三剂接种后显著增加。《神经病学纪事》2022年；91:796 - 800。
